PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial

PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an announcement.

PYC Therapeutics has highlighted progress in its clinical pipeline with new data and trial milestones for PYC-001, its investigational RNA therapy for Autosomal Dominant Optic Atrophy, a rare childhood blinding disease affecting about 1 in 35,000 people and lacking approved treatments. At the North American Neuro-Ophthalmology Society 2026 conference in Boston, safety, tolerability and efficacy results from a Single Ascending Dose study in ADOA patients are being presented, while the company has also initiated a Multiple-Ascending Dose trial, with repeat-dose safety and efficacy readouts planned later in 2026, underscoring its drive to advance a first-in-class treatment in a high-unmet-need ophthalmic niche.

The presentation of early clinical data on PYC-001 and the launch of the repeat-dose study mark a key validation point for PYC’s RNA delivery platform and its broader precision medicine strategy in genetic eye diseases. Positive outcomes from these studies could strengthen the company’s positioning in the competitive RNA therapeutics field, support the value of its expanding clinical portfolio, and provide important signals for patients, clinicians and investors watching the development of a potential first therapy for ADOA.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is an ASX-listed, clinical-stage biotechnology company focused on developing a new generation of RNA-based precision medicines for genetic diseases with no existing treatments. The company leverages a proprietary drug delivery platform to enhance the potency of RNA therapies and concentrates on monogenic indications, which historically show higher probabilities of success in clinical development.

Average Trading Volume: 1,249,365

Technical Sentiment Signal: Buy

Current Market Cap: A$1.31B

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.